tm
Seeing Is Believing
tm
Seeing Is Believing
GLUE is currently covered by 5 analysts with an average price target of $28.5. This is a potential upside of $9.48 (98.19%) from yesterday's end of day stock price of $14.38.
Monte Rosa Therapeutics's activity chart (see below) currently has 22 price targets and 38 ratings on display. The stock rating distribution of GLUE is 14.29% HOLD and 85.71% BUY.
Analysts average stock forecasts to be materialized ratio is 70.93% with an average time for these price targets to be met of 463.27 days.
Highest price target for GLUE is $37, Lowest price target is $22, average price target is $28.5.
Most recent stock forecast was given by MICHAEL SCHMIDT from GUGGENHEIM on 24-Aug-2026. First documented stock forecast 18-Jul-2021.
Currently out of the existing stock ratings of GLUE, 2 are a HOLD (14.29%), 12 are a BUY (85.71%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 02-Jan-2022
$28
$13.44 (92.31%)
$28
Buy Since 07-Jan-2026
$27
$12.44 (85.44%)
$29
Buy Since 14-Feb-2024
$27
$12.44 (85.44%)
$26
Buy Since 19-Jul-2021
$37
$14.71 (65.99%)
$16
Buy Since 15-Aug-2022
$22
$-0.29 (-1.30%)
$20
What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?
Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?
Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?
Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?
